Get the app
US › Healthcare

ARS Pharmaceuticals, Inc (SPRY)

US · Healthcare · Biotechnology

$4.02-1.23%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
$33.7M
Revenue YoY
+114.2%
Net profit
$-62.3M
EPS
$-0.63
EPS estimate
$-0.55
Net margin
-185.2%

EPS came in at -0.63 against a street estimate of -0.55 — a miss of 14.5%.

Key statistics

Market cap
$404.8M
Forward P/E
0.0
P/B
33.26
Book value
$0.13
EPS (TTM)
$-2.18
52-week high
$13.15
52-week low
$3.88
50-day MA
$5.05
200-day MA
$7.85
Beta
1.08

Analyst view

Analysts rate ARS Pharmaceuticals, Inc a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $22.50.

Shareholding

Insiders
16.18%
Institutions
92.08%

Largest institutional holders

FundStake
RA Capital Management, LLC10.92%
Rubric Capital Management LP8.59%
Orbimed Advisors LLC8.33%
Deerfield Management Co7.55%
BlackRock Inc5.34%
Tyro Capital Management LLC4.48%
Aberdeen Group PLC4.19%
SR ONE CAPITAL MANAGEMENT, LP4.04%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for ARS Pharmaceuticals, Inc — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-10-18.